{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:17:02Z","timestamp":1783696622021,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["PNC0000002"],"award-info":[{"award-number":["PNC0000002"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["PNC-E3-2022-23683266 PNC-HLS-DA"],"award-info":[{"award-number":["PNC-E3-2022-23683266 PNC-HLS-DA"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"name":"postgraduate school of Allergy and Clinical Immunology Program, Bari Aldo Moro University.","award":["postgraduate school of Allergy and Clinical Immunology Program, Bari Aldo Moro University."],"award-info":[{"award-number":["postgraduate school of Allergy and Clinical Immunology Program, Bari Aldo Moro University."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mucopolysaccharidosis (MPS) type 1\u00a0S and type 2 are rare lysosomal storage disorders characterized by impaired enzyme production, resulting in glycosaminoglycans accumulation within lysosomes. Enzyme Replacement Therapy (ERT) with laronidase and idursulfase are first line treatments, respectively. However, infusion-related hypersensitivity reactions (HR) may lead to ERT discontinuation. Thus, desensitization can be performed to restore ERT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We report on a two-year follow-up after a combined desensitization approach in two MPS patients experiencing HR to ERT. This approach consists of intravenous rapid desensitization combined with the subcutaneous allergen immunotherapy-like desensitization with the culprit recombinant enzyme.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The first patient, suffering from MPS type I, underwent to the combined desensitization approach, and subsequently tolerated weekly standard laronidase infusions for 13 months when HR occurred again. Then, a monthly omalizumab (anti-IgE monoclonal antibody) administration was implemented allowing the patient to restore ERT. The second patient, diagnosed with MPS type 2, was subjected to a similar combined desensitization strategy with idursulfase, and achieved a total desensitization after one year, confirmed by negative skin tests. Thus, he continued standard ERT infusions without HR occurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The combined desensitization approach proved effective in conferring immunotolerance for at least one year in both MPS patients, also demonstrated by the negative skin tests in one patient. However, when immunotolerance to ERT is lost, omalizumab administration can be a valid option in restoring ERT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03516-z","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:30:07Z","timestamp":1735299007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Two-year follow-up after drug desensitization in mucopolysaccharidosis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-0532","authenticated-orcid":false,"given":"Federico","family":"Spataro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Chaoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Desantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Di Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio Di","family":"Girolamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"3516_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt FM, d\u2019Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27.","journal-title":"Nat Rev Dis Primers"},{"key":"3516_CR2","doi-asserted-by":"publisher","first-page":"e0184065","DOI":"10.1371\/journal.pone.0184065","volume":"12","author":"AD Dornelles","year":"2017","unstructured":"Dornelles AD, Artigal\u00e1s O, da Silva AA, Ardila DLV, Alegra T, Pereira TV, Vairo FPE, Schwartz IVD. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0184065.","journal-title":"PLoS ONE"},{"key":"3516_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, Ramaswami U, Vellodi A, Wraith JE, Cleary M, Gucsavas-Calikoglu M, Puga AC, Shinawi M, Ulbrich B, Vijayaraghavan S, Wendt S, Conway AM, Rossi A, Whiteman DA, Kimura A. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95\u2013101.","journal-title":"Genet Med"},{"key":"3516_CR4","doi-asserted-by":"publisher","first-page":"e13981","DOI":"10.1111\/pai.13981","volume":"34","author":"F Spataro","year":"2023","unstructured":"Spataro F, Carlucci P, Loverre T, Macchia L, Di Bona D. Hypersensitivity reaction during enzyme replacement therapy in lysosomal storage disorders. A systematic review of desensitization strategies. Pediatr Allergy Immunol. 2023;34:e13981.","journal-title":"Pediatr Allergy Immunol"},{"key":"3516_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","volume":"122","author":"MC Castells","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574\u201380.","journal-title":"J Allergy Clin Immunol"},{"key":"3516_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s13023-022-02556-7","volume":"17","author":"F Spataro","year":"2022","unstructured":"Spataro F, Viggiani F, Macchia DG, Rollo V, Tummolo A, Suppressa P, Sabba\u2019 C, Rossi MP, Giliberti L, Satriano F, Nettis E, Di Bona D, Caiaffa MF, Fischetto R, Macchia L. Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS). Orphanet J Rare Dis. 2022;17:402.","journal-title":"Orphanet J Rare Dis"},{"key":"3516_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1067\/mai.2002.128689","volume":"110","author":"J Melamed","year":"2002","unstructured":"Melamed J, Stahlman JE. Rapid desensitization and rush immunotherapy to trastuzumab (herceptin). J Allergy Clin Immunol. 2002;110:813\u20134.","journal-title":"J Allergy Clin Immunol"},{"key":"3516_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/pai.13049","volume":"30","author":"E Arroabarren","year":"2019","unstructured":"Arroabarren E, Aznal E, Anda M, Sanchez-Valverde F. Anaphylaxis after Elosulfase a infusion: omalizumab as coadjuvant for enzyme replacement therapy desensitization. Pediatr Allergy Immunol. 2019;30:491\u20134.","journal-title":"Pediatr Allergy Immunol"},{"key":"3516_CR9","doi-asserted-by":"publisher","first-page":"e2021052648","DOI":"10.1542\/peds.2021-052648","volume":"149","author":"VC D\u00edaz Vidal","year":"2022","unstructured":"D\u00edaz Vidal VC, Gillispie A, Aranda C, Anvari S. Successful elosulfase alfa desensitization protocol in a patient with Morquio A syndrome. Pediatrics. 2022;149:e2021052648.","journal-title":"Pediatrics"},{"key":"3516_CR10","unstructured":"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160909135675\/anx_135675_en.pdf"},{"key":"3516_CR11","doi-asserted-by":"publisher","first-page":"100880","DOI":"10.1016\/j.gore.2021.100880","volume":"38","author":"A Vultaggio","year":"2021","unstructured":"Vultaggio A, Petrella MC, Tomao F, Nencini F, Mecheri V, Marini A, Perlato M, Vivarelli E, De Angelis C, Ferrarini I, Pillozzi S, Matucci A, Antonuzzo L. The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer. Gynecol Oncol Rep. 2021;38:100880.","journal-title":"Gynecol Oncol Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03516-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03516-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03516-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T12:04:39Z","timestamp":1735301079000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03516-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3516"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03516-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"9 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was sought after and obtained from the patients, for publication. The work was carried out in compliance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Federico Spataro, Department of Precision and Regenerative Medicine and Jonic Area, Internal Medicine and Allergology Unit, University of Bari Aldo Moro, Italy","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Signature"}}],"article-number":"491"}}